Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

LONDON/SAN FRANCISCO (Reuters) – Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...

To see weight-based dosing charts for adults and children, see this Valtoco dosage article. If your seizures continue after your first Valtoco dose, your doctor may instruct you to use a second dose.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat ... and some participants reduced their dose due to discomfort. (Picture courtesy: iStock) Covid ...

Dosing a statin (rosuvastatin ... and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from London Novo Nordisk ...

A nation-wide shortage of Ozempic is impacting people with diabetes ability to access the drug, especially in regional and remote Australia. The Therapeutic Goods Administration says there will be ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Amy Schumer once hopped on board the Ozempic trend, but the side effects were so intense she had to stop. During a recent appearance on "The Howard Stern Show," the comedian, 43, opened up about ...